About Gilgamesh Pharma
Gilgamesh Pharma is a private company based in New York, New York, incorporated in 2025 in Delaware. It has reported $68,340,946 raised in four offerings on Form D since February 2026. Its chief executive is Jonathan Sporn.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | Mar 31, 2026 | $2,250,000of $15.0M target | 3 | $750K | Options, Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert.Rule 506(b) | Form D ↗ |
| Mar 9, 2026 | Mar 24, 2026 | $60,000,000fully sold | 40 | $1.5M | Equity, Shares of Preferred Stock of Issuer and the shares of capital stock of Issuer into which such shares of Preferred Stock may convert.Rule 506(b) | Form D ↗ |
| Jan 2, 2026 | Feb 4, 2026 | $6,090,946fully sold | 9 | $676K | EquityRule 506(b) | Form D ↗ |
| Not yet | Feb 4, 2026 | $0of $4.3M target | 8 | $0 | Options, Options to purchase shares of Common Stock of the Issuer and the shares of Common Stock issued upon the exercise thereof.Rule 506(b) | Form D ↗ |
| Total, four offerings | $68,340,946 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Gilgamesh Pharma's Form D filed Mar 31, 2026.
AK
Amy Kruse
Director
Also a prime movers lab and director at Cognixion and a director at Morphoceuticals and Motif Neurotech.
Jonathan Sporn
Founder, CEO and director
PS
ZH
RB
